Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Recruiting now · Phase 1

Conditions studied: Head and Neck Cancer, Oropharyngeal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma

In brief

Patients with head and neck cancer treated with radiotherapy (RT) have a substantial change of recurrence of the tumor in the pharynx or lymph nodes in the neck. Once tumor and/or lymph nodes have recurred, the prognosis is poor. To increase the efficacy of RT, usually chemotherapy is added to the treatment. However, due to age or co-morbidity chemotherapy is not always feasible to give in all patients. In head and neck patients unfit for chemotherapy, there is a clinical need to increase the effectiveness of RT, without adding substantial toxicity. To this end, the use of thermotherapy in this disease site is investigated. The goal of this clinical trial is to learn about the recommended dose of thermotherapy in addition to radiotherapy for patients with head and neck cancer. This recommended dose is the dose that is tolerable and does not give additional side effects. The main question our study aims to answer is: "What is the recommended dose of thermotherapy for patients with primary head and neck cancer treated with radiotherapy?" Participants will receive thermotherapy once a week in addition to the standard radiotherapy. Researchers will investigate if side effects occur during the treatment and until 6 months after the last treatment has been given. The thermotherapy will be applied using a device that was made in Erasmus MC and allows for precise heating of the tumor and lymph nodes.

Key facts

Study ID

NCT06761937

Run by

Erasmus Medical Center

People needed

30

Starts

2025-05-01

Expected to finish

2028-10-31

Last updated by the study team

2025-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >= 18 years
• WHO 0-1
• Mouth opening before treatment of >= 40 mm for women and >= 45mm for men
• Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx proven by cytology / histology.
• Locally advanced disease (stage III-IV).
• Curative intend treatment with radiotherapy in the primary setting with a contraindication for systemic adjuvant treatment.
• Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.
• Written informed consent.

You may not qualify if…

• Patients previously treated by radiation on the same target volume.
• Any condition or circumstance potentially hampering compliance with the follow-up schedule.
• Patients having pacemakers or clustered metal markers (with a total length >2 cm of metal markers in direct contact).
• Tumor location caudal to a tracheostomy (this prevents penetration of the microwaves to the tumor).
• Anatomical boundaries of the shoulders prohibiting positioning of the applicator.

Where it is running

• Erasmus MC — Rotterdam, South Holland, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.